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Abstract: Hypertrophic cardiomyopathy (HCM) is a prevalent and untreatable cardiovascular disease
with a highly complex clinical and genetic causation. HCM patients bearing similar sarcomeric
mutations display variable clinical outcomes, implying the involvement of gene modifiers that regulate
disease progression. As individuals exhibiting mutations in mitochondrial DNA (mtDNA) present
cardiac phenotypes, the mitochondrial genome is a promising candidate to harbor gene modifiers of
HCM. Herein, we sequenced the mtDNA of isogenic pluripotent stem cell-cardiomyocyte models
of HCM focusing on two sarcomeric mutations. This approach was extended to unrelated patient
families totaling 52 cell lines. By correlating cellular and clinical phenotypes with mtDNA sequencing,
potentially HCM-protective or -aggravator mtDNA variants were identified. These novel mutations
were mostly located in the non-coding control region of the mtDNA and did not overlap with those
of other mitochondrial diseases. Analysis of unrelated patients highlighted family-specific mtDNA
variants, while others were common in particular population haplogroups. Further validation of
mtDNA variants as gene modifiers is warranted but limited by the technically challenging methods
of editing the mitochondrial genome. Future molecular characterization of these mtDNA variants in
the context of HCM may identify novel treatments and facilitate genetic screening in cardiomyopathy
patients towards more efficient treatment options.
Keywords: Hypertrophic cardiomyopathy; disease modeling; isogenic human pluripotent stem
cell-derived cardiomyocytes; gene modifiers; mitochondrial DNA; haplogroups
1. Introduction
Hypertrophic cardiomyopathy (HCM) is a prevalent cardiovascular disease characterized by
thickening of the left ventricular wall in the absence of abnormal loading conditions [1]. HCM progresses
through a compensatory response relying on changes in gene expression, bioenergetics and cellular
morphology of cardiomyocytes [2], in order to maintain the cardiac function required to meet the
metabolic demands of the body [3]. HCM presents wide clinical variability, with patient outcomes
ranging from asymptomatic to sudden cardiac death, when the sustained compensatory response
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leads to lethal energetic and functional imbalance [4]. This variation is likely due to the highly complex
genetic causation characteristic of this condition, displaying variable penetrance and expressivity [5].
While approximately half of HCM patients display mutations in one or more of the >20 sarcomeric genes
that regulate cardiomyocyte contraction, others do not exhibit any mutation in known heart-related
genes [6]. Disease manifestation is mutation-specific, with patients with different mutations in the
same gene showing contrasting clinical outcomes [7]. Even monozygotic twins bearing the same
sarcomeric mutation displayed different clinical presentations [8], implying that factors beyond the
single pathological change (e.g., genetic and epigenetic background and environmental modifiers)
contribute to the magnitude of the disease effects [9]. This intricate clinical and genetic complexity of
HCM has impaired the development of efficient therapeutics, with heart transplantation being the
only long-term solution [10,11].
While numerous hallmarks of HCM have been identified [2], disrupted mitochondrial bioenergetics
is commonly associated with heart failure, whereby the inefficient ATP usage in the heart leads to
energy depletion [4]. Despite the fact that the majority of the proteins present in the mitochondria are
encoded by nuclear genes, all the polypeptides, ribosomal RNAs and tRNAs encoded by mitochondrial
DNA (mtDNA) constitute essential subunit complexes of the oxidative phosphorylation (OXPHOS)
system [12]. The heart is a highly energetically-demanding organ that sources 90% of the ATP from
mitochondrial OXPHOS [13]. Consistently, cardiomyocytes have higher mtDNA copy number per
diploid nuclear genome, resulting in increased mitochondrial content [14]. Thus, mitochondrial
diseases impact preferentially in the heart [15], mostly due to pathogenic mtDNA mutations [16] or
reduction in mtDNA content [17]. Importantly, mitochondrial cardiomyopathies (MIC) constitute
phenocopies of HCM, particularly in cases where the genes encoding mtRNAs are mutated [18].
Altogether, we hypothesize that mtDNA is a likely candidate for harboring gene modifiers of HCM,
and it remains unexplored.
We previously developed and characterized parallel isogenic human pluripotent stem cell-derived
cardiomyocyte (hPSC-CM) models of HCM, either displaying the p.R453C-β-myosin heavy chain
(β-MHC) mutation [19], or the p.E99K-ACTC1 pathological change [20]. These two sets have revealed
overall similarities and differences in HCM hallmarks and highlighted variations in functional
phenotypes and gene expression profiles between the different cell lines carrying the same mutation.
Remarkably, both sarcomeric-mutant models exhibited increased mitochondrial respiration rates
relative to isogenic healthy controls, characteristic of the compensatory stage of HCM that precedes
energy depletion [21]. Thus, we utilized these sets of hPSC-CMs to investigate the role of mtDNA
to harbor potential gene modifiers that could underlie the different HCM phenotypes observed.
The identification of novel HCM gene modifiers could unveil new molecular targets for future treatment
and support genetic screening of patients, to better inform clinicians on the most efficient therapy.
2. Experimental Section
2.1. Cell Culture
hPSCs were cultured, characterized and differentiated into cardiomyocytes according to previously
reported monolayer protocols [19,20,22] (all patient skin biopsies were donated via informed consent
under the approval of Research Ethics Committee—number 09/H0408/74). hPSC-CMs at over ~90%
purity were dissociated at Day 20 of culture by collagenase treatment, as previously described [23]
and genomic DNA was extracted using DNeasy Blood and Tissue Kit (Qiagen, Hilden, Germany),
following manufacturer′s instructions.
2.2. Ratiometric qPCR
Real-time qPCR reactions were performed via TaqMan® Gene Expression assays (Applied
Biosystems, Foster City, CA, USA), as previously described [24]. Briefly, 50 ng of genomic DNA was
added to Taqman mastermix containing the probe of interest (NT-ND1: Hs02596873_s1, MT-ND2:
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Hs02596874_g1, ACTB: Hs03023880_g1). Data were analyzed using the 2−∆∆CT method to compare
mtDNA content between healthy lines or the ∆∆CT method between isogenic lines, where the average
of healthy (WT) hPSC-CMs was used for relative quantification [25].
2.3. mtDNA Next Generation Sequencing (NGS) and Analysis
Whole mtDNA NGS was performed as previously described [26]. The reference sequence
for mtDNA used was the revised Cambridge reference sequence (rCRS; GenBank Accession No.
NC_012920.1). PCR integrity was confirmed with agarose gel imaging using two overlapping
long-range PCR products (11,745 and 5277 bp) of the complete 16,569-bp mitochondrial genome,
originating from a total DNA specimen. Sequencing was conducted using an Illumina HiSeq 4000
(Illumina, San Diego, CA, USA) with 51-bp paired-end reads. The Bioinformatics Core at Mayo Clinic
analyzed the mtDNA NGS data using the mitosort pipeline. Briefly, the paired-end reads were aligned to
the rCRS using BWA-MEM v0.7.10. A custom pysam method was used to call single nucleotide variants
and small insertions/deletions with heteroplasmy greater than 1%. The Haplogrep2 method and
PhyloTree 17 were used to assign haplogroups and identify the mtDNA private variants [27,28]. In silico
prediction of the impact of mtDNA mutations in protein structure/function by Polyphen-2, CAROL and
APOGEE was performed via the bioinformatics tool MitImpact3D (https://mitimpact.css-mendel.it/) [29].
The impact of mitochondrial tRNA mutations was evaluated by MITOTIP [30] (part of MITOMAP
database: https://www.mitomap.org/MITOMAP).
2.4. Seahorse Analysis of Mitochondrial Respiration
The Seahorse XF96 extracellular flux analyzer (Agilent Technologies, Santa Clara, CA, USA) was
used to evaluate cardiomyocyte metabolism, as previously described [24], with the values of oxygen
consumption rate (OCR) being normalized to total cell number, quantified by Hoechst33342 (Sigma
#BSS61) staining using fluorescence at 355 nm excitation and 460 nm emission in an automated imaging
platform (CellaVista, Synentec, Elmshorn, Germany).
2.5. Evaluation of Production of Reactive Oxygen Species (ROS) in Mitochondria
Mitochondrial ROS production in live hPSC-CMs was investigated by flow cytometry after staining
with 5 µM MitoSOX Red (#M36008 Life Technologies, Carlsbad, CA, USA) [31]. Live cells were incubated
with the dye (made in Ca2+/Mg2+-rich HBSS (Gibco #14025, Thermo Fisher Scientific, Waltham, MA,
USA)) for 30 min at 37 ◦C and 5% CO2, followed by a PBS wash (Gibco #14190-094, Thermo Fisher
Scientific, Waltham, MA, USA) and centrifugation/ resuspension in PBS. Samples were then stored on ice
for up to 30 min before being run on Astrios flow cytometer (Beckman Coulter, Brea, CA, USA).
2.6. Statistical Analysis
qPCR data are presented as box and whiskers plot representing 5–8 biological replicates performed
in triplicate. Seahorse analysis and MitoSOX intensity is represented as mean± SEM, from 5–7 biological
replicates performed in triplicate. Statistical analysis was performed using GraphPad software (v8.2).
Direct comparison between healthy cell lines was performed using unpaired Student’s t-test. HCM cell
lines were compared to respective isogenic WT lines using unpaired one-way ANOVA test with
Dunnett’s post hoc test for correction of multiple comparisons. Significance tests were based on
p-values as follows: * p < 0.05; ** p < 0.01, *** p < 0.001, and n.s. (non-significant).
3. Results
3.1. Revisiting Isogenic hPSC-CM Models to Investigate Varying HCM Mitochondrial Phenotypes
To address the highly complex genetic causation associated with HCM, isogenic hPSC-CM lines
were previously generated by CRISPR/Cas9 genome editing technology [32], which isolates the impact
of the mutation of interest. This approach was used to introduce the p.R453C-β-MHC mutation [19]
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in three healthy (WT/WT) hPSC lines (AT1-hiPSC, REBL-PAT-hiPSC and HUES7-hESC), resulting in
heterozygote (MUT/WT) and homozygote (MUT/MUT) variants, and a β-MHC-knockout (KO/KO)
(Figure 1a) in a total of 10 cell lines. Previous characterization of the hPSC-CMs generated from these
lines revealed HCM hallmarks of disease (e.g., hypertrophy, hypo-contractility and bioenergetics), but
to a different degree between sets, with the AT1 lines showing the more severe phenotypes relative to
REBL-PAT and HUES7 counterparts [19].
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(b) and one-way ANOVA + Dunnett’s correction relative to WT in (c,d)).
In addition, isogenic hiPSC sets bearing the heterozygous p.E99K-ACTC1 mutation were
generated by correcting patient lines (E99K1 and -2) or introducing the mutation in healthy relatives
(NC-Edit-E99K) [20]. Similar to the β-MHC-mutant model, the magnitude of phenotypes investigated
(e.g., arrhythmogenesis, hyper-contractility and energy depletion) varied between the cell line of origin
(with E99K1 line showing more severe phenotypes than E99K2 and NC-Edit-E99K). In light of the
strong contribution of energy depletion to HCM progression in both models, the mtDNA sequence and
content were investigated and data were related to the differential functional phenotypes previously
observed between separate isogenic sets bearing the same mutation.
A ratiometric qPCR approach was undertaken to assess mitochondrial content in isogenic
p.R453C-β-MHC hPSC-CMs, by analyzing mitochondrial: nuclear DNA ratios [24]. MtDNA content
varied between healthy hPSC-CM lines (Figure 1b), following the same trend as the HCM phenotypic
severity: AT1-cardiomyocytes showed markedly lower mtDNA content relative to REBL-PAT and
HUES7 counterparts. Introduction of the p.R453C-β-MHC mutation in AT1 and REBL-PAT hPSC-CMs
did not alter mtDNA content relative to their healthy isogenic controls, except for the most extreme
genotypes (AT1-β-MHC-KO and partially in REBL-PAT homozygous, Figure 1c,d).
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3.2. Comparison of mtDNA Variants between Phenotyped Isogenic Lines Reveals Potential
HCM Gene Modifiers
As hPSC-CM lines bearing the same mutation showed variations in magnitude of HCM phenotypes,
we hypothesized that these differences could be due to mtDNA mutations tracing back to the cell
source of origin used for disease modeling. Thus, whole mtDNA next-generation sequencing (NGS)
was performed for all the cell lines investigated (from fibroblasts through hPSCs to differentiated
hPSC-CMs). The identification of mtDNA variants through nuclear reprograming and cardiomyocyte
differentiation enables exclusion of mutations that arise as a result of in vitro culture [26], i.e., that do
not play a role in HCM progression.
Analysis of mtDNA NGS data using HaploGrep software revealed clear differences between the
three starting hPSC lines used for p.R453C-βMHC HCM modeling, consistent between all the lineages
(Figure 2). These encompassed different types of mutations (deletions (DELs), insertions (INSs) and
single nucleotide variants (SNVs)) and heteroplasmy, with some only being introduced or lost upon
in vitro culture (and thus deemed artefactual for HCM). To predict the impact of these mutations in
protein structure/function, we utilized PolyPhen-2, CAROL and APOGEE, as these were among the top
in silico prediction performers [29,33]. In addition, the impact of Mt-tRNA variants was predicted by
MITOTIP [30]. However, all of the potentially HCM-relevant mutations were located in the non-coding
control region of the mtDNA genome (Table 1), preventing in silico prediction.J. Clin. Med. 2020, 9, x FOR PEER REVIEW 7 of 18 
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and HUES7 (bottom) identified variants specific to the starting cell sources. Legend map on the right
side indicates type of mtDNA mutation (DEL, deletion; INS, insertion; SNV, single nucleotide variant)
and percent heteroplasmy is correlated with the size of the symbol (WT, wild-type; het, heterozygous;
HOM, homozygous; KO, knock-out).
Table 1. mtDNA variants identified by NGS in p.R453C-β-MHC isogenic lines used for HCM modeling
(WT, healthy; het, heterozygous; HOM, homozygous; KO, knockout). In silico pathogenicity prediction
algorithms used: § MitoTIP; * Polyphen-2; † CAROL; ‡ APOGEE. Phenotypically severe hPSC-CM line
is highlighted in red and less severe ones in green.
Isogenic hPSC-CM Set(s) Locus mtDNA Mutation Percent Heteroplasmy(WT-Het-HOM-KO)
In silico Prediction
(Score) Potential HCM Effect
AT1 MT-HV2,MT-OHR m.152T > C 99.9 (all lines)
N/A
(non-coding)
Aggravator (present
only in AT1s)
REBL-PAT + HUES7
MT-HV2,
MT-OHR,
MT-CSB2
m.309_310insCCT REBL-PAT: 28.9–26.4–27.2HUES7: 17.4–13.8–15.6
N/A
(non-coding)
Protective (absent
in AT1)
HUES7
MT-HV2,
MT-OHR,
MT-CSB2
m.309_310insCCCT 11.7–11.6–13.3 N/A(non-coding)
Protective (absent
in AT1)
AT1 + REBL-PAT + HUES7
MT-HV2,
MT-OHR,
MT-CSB2
m.310T > C
AT1: 15.0–17.1–14.5–17.0;
REBL-PAT: 61.2–63.2–61.9;
HUES7: 61.6–56.4–57.6
N/A
(non-coding)
Protective (less prevalent
in AT1)
AT1 + REBL-PAT + HUES7
MT-HV2,
MT-OHR,
MT-CSB2
m.310_311insC
AT1: 67.8–64.2–65.6–63.9
REBL-PAT: 30.1–26.7–27.2
HUES7: 26.1–32.0–33.3
N/A
(non-coding)
Aggravator (more
prevalent in AT1s)
AT1 MT-HV3 m.514_515delCA 60.1–53.5–53.6–53.7; N/A(non-coding)
Aggravator only present
in AT1s)
REBL-PAT MT-RNR2 m.2203G > A 14.5% N/A(non-coding)
None: acquired during
reprogramming
AT1 MT-RNR2 m.2525C > T Fibroblasts: 12.1%iPSCs + iPSC-CMs: 99.9%
N/A
(non-coding)
None: increased upon
nuclear reprogramming
AT1 + REBL-PAT + HUES7 MT-TA m.5597A > C
AT1: 5.4–12.4–6.5–11.4;
REBL-PAT: 11.1–14.3–13.2;
HUES7: 24.8–7.8–8.8
Possibly pathogenic
(73.80%) §
None: acquired during
reprogramming/culture
HUES7 MT-CO1 m.5938A > C 12.2–1.2–1.1
Probably damaging
(1.000) *
Deleterious (1) †
Neutral (0.45) ‡
None: acquired during
culture
REBL-PAT MT-HV1 m.16319G > A 99.7–99.7–99.6 N/A(non-coding)
Protective (absent
in AT1)
To understand the contribution of the identified mutations to HCM progression, the heteroplasmy
levels between hPSC-CMs were related to the known phenotype severities (AT1 more severe than
REBL-PAT and HUES7 [19]). Interestingly, some mutations were only present in the AT1 samples
(m.152T > C, m.514_515delCA) deeming them as potential aggravators. Contrarily, others were only
identified in REBL-PAT and HUES7 lines (m.309_310insCCT, m.309_310insCCCT and m.16319G > A),
rendering them potential protective gene modifiers. Lastly, some variants were present in all lines,
with varying heteroplasmy levels following a clear trend (e.g., m.310T > C, lower in AT1 than
REBL-PAT and HUES7—potentially protective; m.310_311insC, higher in AT1 than REBL-PAT and
HUES7—likely aggravator).
The same strategy was applied to the three isogenic pairs (E99K1, E99K2 and NC-Edit-E99K)
bearing the heterozygous p.E99K-ACTC1 mutation. Analysis of NGS of mtDNA highlighted different
variants between lines (Figure 3), with the majority being located in the non-coding control region
(Table 2). This approach identified a variant exclusively in the E99K1 line (m.11176G > A), with
another being shared with the AT1 line bearing the p.R453C-βMHC sarcomeric mutation (m.152T > C),
making both strong candidates as potential HCM aggravators. Remarkably, some heteroplasmic
mutations were common between the most severe p.E99K-ACTC1 (E99K1 line) and the milder
p.R453C-β-HMC models (REBL-PAT and HUES7 lines), suggesting opposite potential effect in
HCM progression: m.309_310insCCT, m.309_310insCCCT, m.310T > C and m.310_311insC. Finally,
some variants were only detected in the NC-Edit-E99K and E99K2 lines (m.8952T > C; m.12715A > G),
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where HCM phenotypes were less acute or non-existent [20], indicating a potentially cardioprotective
modifier function. The identified correlations between mtDNA variants and phenotypic severity across
multiple isogenic hPSC-CM lines bearing different sarcomeric mutations strongly support the role of
the non-coding control region to harbor gene modifiers of HCM.J. Clin. Med. 2020, 9, x FOR PEER REVIEW 8 of 18 
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percent heteroplasmy is correlated with the size of the symbol. (WT, wild-type; het, heterozygous).
J. Clin. Med. 2020, 9, 2349 8 of 17
Table 2. mtDNA variants identified by NGS in p.E99K-ACTC1 isogenic lines used for HCM modeling
(WT, healthy; het, heterozygous). In silico pathogenicity prediction algorithms used: § MitoTIP; *
Polyphen-2; † CAROL; ‡ APOGEE. Phenotypically severe hPSC-CM line is highlighted in red and less
severe ones in green.
Isogenic hPSC-CM Set(s) Locus mtDNA Mutation Percent Heteroplasmy(WT-Het)
In silico Prediction
(Score) Potential HCM Effect
E99K1 MT-HV2,MT-OHR m.152T > C 99.3–99.9
N/A
(non-coding)
Aggravator
(present only in E99K1)
E99K1
MT-HV2,
MT-OHR,
MT-CSB2
m.309_310insCT 15.3–25.3 N/A(non-coding)
Aggravator
(present only in E99K1)
E99K1
MT-HV2,
MT-OHR,
MT-CSB2
m.309_310insCCT 18.8–9.3 N/A(non-coding)
Aggravator
(present only in E99K1)
E99K1 + NC-EDIT-E99K +
E99K2
MT-HV2,
MT-OHR,
MT-CSB2
m.310T > C
E99K1: 60.6–59.9
NC-EDIT-E99K: 17.0–16.3
E99K2: 17.5–16.4
N/A
(non-coding)
Aggravator
(more prevalent
in E99K1)
E99K1 + NC-EDIT-E99K +
E99K2
MT-HV2,
MT-OHR,
MT-CSB2
m.310_311insC
E99K1: 26.6–27.2
NC-EDIT-E99K: 61.6–62.7
E99K2: 63.6–61.7
N/A
(non-coding)
Protective (less prevalent
in E99K1)
E99K1 + NC-EDIT-E99K +
E99K2 MT-TA m.5597A > C
E99K1: 9.6–9.6
NC-EDIT-E99K: 7.5–6.9
E99K2: 10.2–7.1
Possibly pathogenic
(73.80%) §
None (present in
all lines)
NC-EDIT-E99K + E99K2 MT-ATP6 m.8952T > C NC-EDIT-E99K: 99.9–99.9E99K2:100–99.9
N/A
(redundant)
Protective (absent
in E99K1);
E99K1 MT-ATP6 m.9116T > C 100–99.5
Benign
(0.000) *
Neutral (0.8) †
Neutral (0.42) ‡
None (benign mutation)
E99K1 MT-ND4 m.11176G > A 99.9–99.2 N/A(redundant)
Aggravator (only
present in E99K1)
NC-EDIT-E99K + E99K2 MT-ND5 m.12715A > G NC-EDIT-E99K: 99.8–99.8E99K2: 99.9–99.7
Benign (0.1) *
Neutral (0.47) †
Neutral (0.28) ‡
Protective (absent
in E99K1)
To test whether these mtDNA variants had a non-specific mito-modulating effect, mitochondrial
respiration was evaluated in the healthy hPSC-CM lines under study using the Seahorse platform
(Figure 4a–d). Interestingly, the cell lines showing less pronounced phenotypes upon the introduction
of the sarcomeric mutations (i.e., REBL-PAT and NC) showed higher baseline mitochondrial respiration
activity relative to more affected hiPSC-CM lines (AT1 and E99K1), in line with the higher mtDNA
content displayed (Figure 1b). This highlights the role of mtDNA variants to HCM progression: while
the identified mutations were not the cause of the cellular phenotypes previously observed (as they
are shared between healthy and diseased hPSC-CMs), they contribute to varying baseline levels of
OXPHOS in healthy mitochondria, suggesting their involvement as gene modifiers. The isogenic
approach used herein enables the investigation of mtDNA mutations shared by unrelated cell lines (in
addition to variants in the nuclear genome, which were not addressed in this study).
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Figure 4. Mito-modulating effects of mtDNA variants identified in hPSC-CMs. (a) Mitochondrial
respiration was evaluated by Seahorse analysis of healthy hPSC-CM lines used to model the p.R453C-βMHC
sarcomeric mutation, showing (b) higher oxidative phosphorylation activity in REBL-PAT cardiomyocytes
relative to the AT1 line, presenting different mtDNA variants. (c,d) The healthy (gene-corrected) E99K1-WT
hPSC-CM line showed lower mitochondrial respiration activity relative to NC hPSC-CMs displaying
diverse mtDNA variants. (e,f) Evaluation of mitochondrial ROS production by flow cytometry of
MitoSOX-labelled hPSC-CMs showed no difference between healthy AT1 vs REBL-PAT hPSC-CMs,
indicating that the mtDNA variants identified in these lines do not contribute to mito-dysfunction. Data
are presented as mean ± SEM, N = 5-7 biological replicates, * p < 0.05, ** p < 0.01, *** p < 0.001, n.s.,
non-significant (Student’s t-test); OCR, oxygen consumption rate.
In addition, we investigated whether the identified mtDNA variants were associated with global
mito-dysfunction, by performing live cell flow cytometry of 5 µM MitoSOX-labeled hPSC-CMs,
which indicates the presence of reactive oxygen species (ROS) in the mitochondria [31]. Elevated
mitochondrial ROS levels cause damage to biological macromolecules and mtDNA mutations, as the
mitochondrial genome is in close proximity of the inner membrane where ROS are produced [34].
However, analysis of the mean intensity of MitoSOX showed similar levels between healthy AT1 and
REBL-PAT hPSC-CMs (Figure 4e,f), indicating that global mito-dysfunction was neither associated
with the differences in magnitude in the cellular phenotypes between lines nor with the existence of
different mtDNA variants between them.
3.3. MtDNA Sequencing Shows Common Variants in Unrelated HCM Patients
To improve our understanding of variability of HCM outcomes between patients, we extended the
investigation of the p.E99K-ACTC1 lines to three unrelated families where that sarcomeric mutation
was predominant. Skin punch biopsies were obtained from 13 individuals (Figure 5a–c), comprising 3
healthy (Samples NC, 10 and 14, in green) and 10 HCM patients, three of which showed more severe
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in vitro phenotypes (sample E99K1) or NYHA classification II (Samples 9 and 13, in red), while the
remainder were classed as NYHA-I (in blue). NGS of mtDNA derived from isolated fibroblasts from
these patients reflected expected maternal inheritance patterns (e.g., Sample 7 descending from Sample
6 and Samples 16 and 18 inheriting from Sample 17, Figure 5d), and revealed different mutations
between individuals. In-depth analysis of these mtDNA variants (Tables S1–S3) showed that, while
some mutations were present in all three families at different heteroplasmy levels (m.310T > C,
m.310_311insC and m.5597A > C), others were common between two (e.g., m.310_311insC and
m.513_514insCACA) or even restricted to some members of only one family (e.g., m.9025G > A).
The fact that specific mtDNA mutations are shared between unrelated families with similar clinical
severity further supports the involvement of mtDNA in HCM progression.
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derived from patient skin biopsies identified variants shared between patients or specific to individual
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SNV, single nucleotide variant) and percent heteroplasmy is correlated with the size of the symbol.
3.4. The Identified mtDNA Mutations Are Novel for HCM, But May Be Common in Some Haplogroups
The contribution of mtDNA variants to cardiomyopathy progression remains vastly unexplored,
with most of the information deriving from mitochondrial neuromuscular diseases [17]. To further
ascertain whether the mtDNA mutations identified in the hPSC-CM lines and patient families
contribute to HCM, we compared them with the few existing reports where the mtDNA of patients
presenting cardiac phenotyp s was sequenced [18,26 35,36]. In ition, we cross-refer nced the
most comprehensive bioinformatics dat of mtDNA v riant associated with hum n disease
(https://w .mito ap.org/ ITOMAP). Remarkably, there was no overlap between the mtDNA
mutations identified herein and those detected in patients with abnormalities in cardiac function or
exhibiting any other mitochondrial diseases.
As none of the identified mtDNA mutations were previously detected in any disease, we further
utilized MITOMAP [37] to investigate the prevalence of these polymorphisms in the human population
and/or within haplogroups. This database entails over 50,000 full-length mtDNA sequences and over
73,000 control region mtDNA sequences. We focused on the mtDNA mutations detected across the
hPSC-CM lines hat suggested modifier effects on HCM (Table 3). The detected variants do not belong
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to each sample haplogroup and were classified by HaploGrep depending on whether or not they are
found in other haplogroups as “local” or “global” private mutations, respectively [26].
Table 3. Prevalence of mtDNA mutations identified in hPSC-CMs using MITOMAP database. Green,
potential HCM protective variants; red, potential HCM aggravator variants.
mtDNA Mutation Variant Type
Percent Variant
Frequency (Full
Length
Sequences)
Percent Variant
Frequency
(Control Region
Sequences)
Found at
Haplogroups at
50% or Higher
m.152T > C Local 26.5 17.6 Yes
m.309_310insCT Global 26.4 16.4 Yes
m.309_310insCCT Global 7.1 4.9 Yes
m.309_310insCCCT Global 0.1 0.2 No
m.310T > C Local 40.7 27.8 Yes
m.310_311_insC Global 0.0 0.0 No
m.514_515delCA Global 24.2 1.7 No
m.8952T > C Local 0.0 N/A No
m.12715A > G Local 0.1 N/A No
m.16319G > A Local 5.9 8.0 Yes
These ten mutations showed variable frequency in the mtDNA sequences deposited in
the MITOMAP database, ranging from rare (m.309_310insCCCT; m.310_311_insC; m.8952T > C;
m.12715A > G) to more prevalent (m.152T > C; m.309_310insCT; m.310T > C) incidence. However, half
of them are enriched (over 50% frequency) in specific haplogroups (Tables S4–S8). Importantly, clinical
studies have indicated that the haplogroup H is found in higher frequency in HCM probands, indicating
a susceptibility factor, whereas haplogroups J, K and UK are uncommon in patients, representing
protective factors [38]. Remarkably, all the variants identified in hPSC-CMs as potential HCM modifiers
were enriched in haplogroup H, with variants m.152T > C and m.310T > C also being common
in haplogroups J and K. This overlap between the cellular model and patient cohort data further
supports our hypothesis that the identified mtDNA variants may contribute as risk modifiers for
HCM. This suggests that HCM patients belonging to these haplogroups are likely to show different
clinical outcomes, depending on whether the mtDNA mutation they present is a potential aggravator
or protective to the disease progression.
4. Discussion
To achieve a deeper understanding of pathological mechanisms of HCM, several models of disease
have been developed, ranging from preparations of scarcely available human heart tissue biopsies to
whole animals [39]. Recent technological advances have resulted in the application of hPSC-CMs for
disease modeling, advantageous relative to previous models due to the ability to provide an unlimited
source of cardiomyocytes and recapture patient genetic makeup [40]. Genome editing technologies
such as CRISPR/Cas9 have facilitated the generation of high-fidelity HCM models, surpassing the
inherent genetic and epigenetic baseline variation between unrelated hPSC-CM lines [41]. Isogenic sets
of hPSC-CM models have therefore addressed the complex genetic etiology characteristic of HCM and
corroborated clinical observations, highlighting that disease progression is mutation-specific [21] and
dependent on factors beyond the primary mutation [20,42].
Early approaches aiming to establish genotype-phenotype relationships in HCM relied heavily on
high numbers of patients in order to associate genetic variants with disease severity, due to the existence
of confounding factors such as age and donor variability [43]. Remarkably, the use of multiple isogenic
cell lines sharing the same sarcomeric mutation in different genetic backgrounds has complemented
patient cohort studies by facilitating the determination of the penetrance and expressivity associated
with that variant. Importantly, the controlled genetic background of this approach overcomes the
need for high numbers of patient cohorts and enables the identification of novel gene modifiers of
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HCM that may constitute new therapeutic targets. We have contributed to this goal by generating
and characterizing two models of HCM bearing different sarcomeric mutations (p.R453C-βMHC or
p.E99K-ACTC1) in six unrelated healthy hPSC cell lines [19,20]. These two models exhibited the main
functional hallmarks of HCM (hypertrophy, energy depletion, arrhythmias and changes in contractility)
and showed variation in the magnitude of in vitro cellular phenotypes observed between isogenic
sets sharing the same mutation. Due to the fact that energetic imbalances in the heart trigger heart
failure in HCM patients [4] and that genetic abnormalities in mtDNA can recapitulate cardiomyopathy
phenotypes [16], we investigated mtDNA as a likely candidate for harboring gene modifiers of HCM.
While sequencing mtDNA of a large cohort of patients would have been advantageous to
provide a higher degree of patient-wide validation, the alternative use of isogenic sets of hPSC-CM
lines enables a more refined investigation of the contribution of mtDNA mutations to HCM, a
disease characterized by highly complex mutation-specific effects [21]. Additionally, the customary
investigation of patient peripheral blood as an alternative to scarcely available cardiac tissue biopsies
is not optimal due to tissue-specific mtDNA sequence heteroplasmy [44] (which is recapitulated in
hPSC-CMs). Notwithstanding, the use of cell lines instead of patient DNA for mitochondrial genetics
studies also presents some drawbacks such as unintended mtDNA mutagenesis and changes in
heteroplasmy that may arise during reprogramming, long-term culture, and cardiac differentiation [26].
Nevertheless, these technical artefacts were minimized by: (i) applying the same culture conditions
across all the cell lines under study; (ii) directly comparing isogenic cell lines where the genetic
background is preserved (impossible in patient samples); and mostly by (iii) sequencing all the
lineages from patient-derived fibroblasts, through hPSCs and hPSC-CMs to identify HCM-unspecific
mtDNA mutations. Additionally, we extended our findings from hPSC-CMs to three unrelated patient
families exhibiting the p.E99K-ACTC1 mutation, providing further evidence that NGS of cell lines may
complement that of patient DNA.
NGS analysis of mtDNA derived from isogenic sets of healthy and HCM hPSC-CMs revealed
11 variants in the p.R453C-βMHC model and 10 in the p.E99K-ACTC1 set. However, in silico prediction
combined with sequencing all the lineages from fibroblasts to hPSCs and hPSC-CMs resulted in the
exclusion of four in the former model and two in the latter. By correlating previously reported
functional disease phenotypes [19,20] with variant heteroplasmy analyzed herein, we identified
potential HCM aggravators and protective mtDNA mutations in both models. Typically, cells can
withstand a high proportion of mutant:WT mtDNA ratios, but when that proportion exceeds the
disease thresholding effect (specific for each variant), OXPHOS defects occur [45].
Moreover, some mtDNA mutations were complete, totally abolishing WT copies. While some of
such variants were specific to each model (such as m.12715A > G as potentially cardioprotective), one
was shared between them (m.152T > C) as a highly likely disease aggravator. Conversely, four variants
showed opposing potential effects in the two models, reinforcing the notion that HCM exhibits complex
genetic causation. We speculate that these variants reflect the contrasting changes in phenotype
induced by the two primary sarcomeric mutations, e.g., while the p.R453C-βMHC change caused
hypo-contractility, the p.E99K-ACTC1 mutation led to hyper-contractility [21].
Importantly, some of the variants identified in hPSC-CMs were enriched in specific haplogroups,
complementing patient cohort studies that highlighted the haplogroup H as a susceptibility factor due
to its higher prevalence in HCM patients [38]. As the identification of the specific mtDNA variants
underlying these differences is lacking [46], further validation of their role in HCM in hPSC-CMs may
contribute to refining this association.
To extend the drawn correlations to a wider patient population, three unrelated families where
p.E99K-ACTC1 (and consequently HCM) were common were investigated, unveiling a number
of shared or family-exclusive mtDNA mutations that may underlie variation in clinical outcomes.
However, when compared to the bioinformatics databases focused on human diseases caused by
mtDNA mutations, none of the identified variants were overlapping. Moreover, MIC patients
presenting cardiomyopathy phenotypes have not showed mutations in the non-coding control region
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of mtDNA [18]. This implies that whilst mtDNA mutations are central to MIC and constitute the main
cause of disease, they are not sufficient to induce HCM, unlike sarcomeric mutations. Nonetheless,
they can exacerbate or improve clinical outcomes, as was illustrated in more severe hypertrophy
phenotypes (~72% higher intraventricular septum thickness) in patients showing both sarcomeric
(p.R249Q-βMHC) and mitochondrial (m.4300A > G) mutations relative to those bearing only one of
them [47]. The same applies to changes in mitochondrial content: while MIC patients showed striking
phenotypes in terms of maladaptive mitochondrial proliferation (e.g., ~3-fold increase in mtDNA
content per cell relative to healthy samples [48]), no conclusive evidence has shown variations in
mtDNA content in explanted failing hearts when compared to healthy counterparts [49], in line with
our data from hPSC-CMs.
To fully demonstrate their role in disease progression, gain- or loss-of-function studies should be
performed, whereby the mtDNA mutations are corrected or introduced in hPSC-CMs. This was not
done in the scope of this study because precise genomic correction of mtDNA mutations is technically
very challenging and has not yet been achieved robustly and efficiently [50,51]. CRISPR/Cas9
approaches rely on homologous recombination (HR) of double stranded breaks (DSBs) to introduce
SNVs of interest [52]. However, unlike in the nuclear DNA, DSBs in mammalian mtDNA cannot be
efficiently repaired by HR [53], precluding the use of CRISPR/Cas9 [54]. mtDNA molecules bearing
DSBs are rapidly degraded and the remaining intact molecules replicate to restore a steady mtDNA
copy number, shifting the heteroplasmic ratio [55]. This strategy has been explored by engineering
restriction endonucleases directed to the mitochondria [56,57] to degrade mutant mtDNA. While this
approach may be partially feasible in the case of heteroplasmic mutations, it is ineffective for those
where the total mtDNA is mutated (such as m.152T > C and m.16319G > A identified in this study).
Alternatively, another possibility is the delivery of healthy plasmid DNA to the mitochondria. However,
the efficient transport of nucleic acids into this organelle remains elusive, even when conjugated with
mitochondriotropic delivery systems [58]. Clearly, a technological breakthrough is required for efficient
and precise genomic correction of mtDNA mutations in MIC and HCM patients.
5. Conclusions
Taken together, by correlating mtDNA variant heteroplasmy with observed in vitro phenotypes
and clinical information, this study identified a number of novel gene modifiers that may potentially
contribute to the clinical outcome of HCM. In addition, specific patient haplogroups bearing the
identified mtDNA variants may be at a higher or lower risk of progressing HCM to heart failure.
This adds another layer of complexity to efficient treatment decision: not only should clinicians consider
sarcomeric mutation-specific effects, but also the existence of gene modifiers that could exacerbate or
ameliorate clinical outcomes. This raises the possibility of performing genetic screening for mtDNA
mutations, which is also useful to distinguish between HCM and MIC patients (particularly in cases
with unexplained hypertrophy without fulfilling standard criteria for HCM, such as symmetrical
hypertrophy with absence of left ventricular outflow tract obstruction) [1]. Overall, this report illustrates
the involvement of hitherto unexplored modifiers of HCM, paving the way for future functional studies
addressing the high complexity of this cardiovascular disease.
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